Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003228 | 0.98 | NR1H4 (0.50) | NR1H4POLBTSHRALDH1A1MAPT | |
| SCHEMBL2002892 | 0.95 | NR1H4 (0.54) | NR1H4POLBTSHRALDH1A1MAPT | |
| SCHEMBL30437182 | 0.90 | NR1H4 (0.49) | NR1H4TSHRALDH1A1MAPTTP53 | |
| SCHEMBL19899941 | 0.90 | NR1H4 (0.49) | NR1H4TSHRALDH1A1MAPTTP53 | |
| SCHEMBL30437437 | 0.88 | MAPT (0.60) | NR1H4POLBTSHRALDH1A1MAPT | |
| SCHEMBL19900665 | 0.88 | MAPT (0.60) | NR1H4POLBTSHRALDH1A1MAPT | |
| SCHEMBL1999960 | 0.87 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL2003480 | 0.84 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL19899889 | 0.84 | NR1H4 (0.51) | NR1H4POLBMAPTTP53 | |
| SCHEMBL19900366 | 0.84 | NR1H4 (0.43) | NR1H4ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2079307-A2 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885POLB 4726/4885TSHR 486/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885POLB 4726/4885TSHR 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.